| Insider | Role | Shares | Value | Buys | Sells |
|---|---|---|---|---|---|
| Date | Ticker | Insider | Role | Type | Shares | Price | Value | Chg% | SEC |
|---|---|---|---|---|---|---|---|---|---|
| Insider | Role | Shares | Value | Buys | Sells |
|---|---|---|---|---|---|
| Date | Ticker | Insider | Role | Type | Shares | Price | Value | Chg% | SEC |
|---|---|---|---|---|---|---|---|---|---|
Director
1 company
Torsten Rasmussen last filed a Form 4 in June 2015, as Director at ACAD. Torsten Rasmussen's net worth is not public. Form 4 filings only show shares in the companies where this person was an insider, as of the last filing.
At the last filing, the largest reported position was 8,500 shares of ACAD. The ACAD filings lean toward selling, a net 31,752 shares.
Torsten Rasmussen has 3 Form 4 filings on record from January 2015 to June 2015, all as Director at Acadia Pharmaceuticals (ACAD), 2015.
The 8 reported transactions were 5 option exercises, 2 open-market sales and 1 option or other derivative award.
Counted by filing, the open-market trades come to no purchases and 2 sales worth about $1.1M.
The largest open-market sale was 19,847 shares of ACAD at an average $35.05 on February 17, 2015, about $696K.
Shares as reported in the last Form 4 for each company; the most recent is from June 2015. Values use today's prices. Any trades after the last filing were not reported, so current holdings may differ.